Last reviewed · How we verify

NCT03532945

A Follow-up Study to Evaluate the Efficacy and Safety of Novomax in Posterior Lumbar Interbody Fusion

Completed NA Last updated 22 May 2018
What this trial tests

NA trial testing Bioactive Glass-Ceramic Spacer in Degenerative Lumbar Spinal Stenosis in 62 participants. Completed in 7 April 2016.

Timeline
28 October 2010
Primary endpoint
13 September 2013
7 April 2016

Quick facts

Lead sponsorBioAlpha Inc.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment62
Start date28 October 2010
Primary completion13 September 2013
Estimated completion7 April 2016

Drugs / interventions tested

Conditions studied

Sponsor

BioAlpha Inc.

Who can join

Adults 30 to 80, any sex, with Degenerative Lumbar Spinal Stenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a long-term follow-up study for more than 3 years to evaluate the efficacy and safety of bioactive glass-ceramic intervertebral spacer (Novomax) in posterior lumbar interbody fusion.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. A Long-Term Follow-up, Multicenter, Comparative Study of the Radiologic, and Clinical Results Between a CaO-SiO2-P2O5-B2O3 Bioactive Glass Ceramics (BGS-7) Intervertebral Spacer and Titanium Cage in 1-Level Posterior Lumbar Interbody Fusion.
    Lee JH, Kim SK, Kang SS, Han SJ, et al · · 2020 · cited 12× · PMID 32080009 · DOI 10.1097/bsd.0000000000000950

Verify or expand the search:

Other recruiting trials for Degenerative Lumbar Spinal Stenosis

Currently open trials in the same condition.

Other BioAlpha Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03532945.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing